Pembrolizumab has shown a manageable toxicity profile with less than 10% of grade 3 or 4 adverse events and pneumonitis incidence of less than 4% with a severity of grade 3 to 5 in half the patients.
The most important question is: this treatment is indicated for whom?
Read more here.
No comments:
Post a Comment